Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3819-25. doi: 10.1016/j.bmcl.2007.05.060. Epub 2007 May 23.

Abstract

Based on the lead compound BX-517, a series of C-4' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds.

MeSH terms

  • 3-Phosphoinositide-Dependent Protein Kinases
  • Cell Line, Tumor
  • Humans
  • Indoles / chemistry*
  • Indoles / pharmacology
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Urea / analogs & derivatives*
  • Urea / chemistry
  • Urea / pharmacology

Substances

  • BX 517
  • Indoles
  • Protein Kinase Inhibitors
  • Urea
  • 3-Phosphoinositide-Dependent Protein Kinases
  • PDPK1 protein, human
  • Protein Serine-Threonine Kinases